ADC Therapeutics Signs a License Agreement with Adagene for its SAFEbody Technology
Shots:
- Adagene to receive upfront- development & commercial milestones- research funding and royalties on sales with certain commercialization rights for Greater China. ADC Therapeutics to utilize Adagene’s SAFEbody technology generating Abs that will further combine with its pyrrolobenzodiazepine (PBD) cytotoxic payload technology to develop masked ADCs for solid tumors
- ADC Therapeutics also has an option to utilize SAFEbody technology for one additional exclusive target. The programs will focus on the targets in which healthy tissue expression prevent the development of ADCs
- SAFEbody technology produces masked ADCs that binds with an antigen in tumor tissues only enhancing the specificity of an ADC with minimization in off-target toxicity on healthy cells
Ref: ADC Therapeutics | Image: ADCReview
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com